<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1657">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139589</url>
  </required_header>
  <id_info>
    <org_study_id>W21_466#21.518</org_study_id>
    <nct_id>NCT05139589</nct_id>
  </id_info>
  <brief_title>The ENDOCARDITIS AUMC Data Collection</brief_title>
  <acronym>ENDO_AUMC</acronym>
  <official_title>The ENDOCARDITIS AUMC Data Collection : a Matched Cohort Study on Perioperative Coagulation in Conservatively and Surgically Treated Patients With Valvular Dysfunction, With and Without Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endocarditis is a challenging clinical condition, with an incidence of 2-10/ 100 000 people.&#xD;
      Desptite optimised treatment, the incidence is rising and mortality in the first year is very&#xD;
      high (~30%).Perioperative coagulation management is difficult, with hypercoagulability and&#xD;
      clotting cascade abnormalities. These can lead to thrombotic complications and reduced&#xD;
      heparin sensitivity. In addition, long bypass times can lead to an increased risk of&#xD;
      coagulation disorders, transfusions and mortality.&#xD;
&#xD;
      We will compare patients with and without infective ndocarditis undergoing valve surgery and&#xD;
      evaluate factors that may help us optimise perioperative care of these high-risk patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infective endocarditis (IE) is a challenging clinical condition, with an incidence of ca.&#xD;
      3-10 per 100 000 people (1) while incidence is supposed to be rising (2). Despite optimized&#xD;
      treatment, mortality is still strikingly high (30% within one year)(3). Thromboembolic&#xD;
      complications are among the most feared complications in IE, and an altered haemostasis seems&#xD;
      to play a crucial role in the pathophysiology (4). In case of progressive valve dysfunction&#xD;
      leading to heart failure, uncontrolled infection and high embolization risk, cardiac surgery&#xD;
      is indicated. This is the case in ca. 40-50% of patients with IE (5).&#xD;
&#xD;
      Perioperative anticoagulation management in surgical IE patients is challenging. On the one&#xD;
      hand, a preoperative hypercoagulability, reduced antithrombin III activity, enhanced platelet&#xD;
      activity/damage, and impaired fibrinolysis can lead to thrombotic complications and heparin&#xD;
      resistance (6), (7), (8), requiring higher heparin doses and/or antithrombin substitution (9)&#xD;
      and likewise increasing the risk for thromboembolic events (10). On the other hand, IE&#xD;
      involving more than one valve or the formation of cardiac abscesses can lead to cumbersome&#xD;
      surgery requiring long cardiopulmonary bypass and cross-clamp time, which in turn increases&#xD;
      the risk for coagulation disorders and transfusion (11), as well as mortality (12).&#xD;
      Furthermore, in aortic valve surgery, transfusion rates in patients with endocarditis were&#xD;
      significantly higher than in patients without endocarditis. After adjustment for risk factors&#xD;
      however, endocarditis of the aortic valve was not independently associated with blood&#xD;
      transfusion. Hence, although endocarditis might not be an independent predictive variable,&#xD;
      well known risk factors associated with endocarditis, and increased surgical complexity have&#xD;
      been proposed to predict blood transfusion requirements in aortic valve surgery (13).&#xD;
&#xD;
      To date, although few studies have focused on coagulation abnormalities in IE in general,&#xD;
      there is a striking paucity of data on the perioperative period. In the recent years,&#xD;
      point-of care coagulation testing, such as rotational thromboelastometry (ROTEM) have been&#xD;
      established in cardiac surgery and shown to reduce transfusion rate when used with an&#xD;
      adequate algorithm (14).&#xD;
&#xD;
      The aim of this study is to examine the differences between patients with and without&#xD;
      endocarditis who undergo cardiothoracic (valve) surgery. In addition, we will look at the&#xD;
      differences between endocarditis patients who undergo surgery, and those who are treated&#xD;
      conservatively. We will look at incidence and degree of perioperative coagulation&#xD;
      abnormalities, as well as transfusion and coagulation factor requirements, heparin&#xD;
      resistance, bleeding scores, predictive endocarditis mortality scores, vasopressor-inotrope&#xD;
      scores, and relate these where possible to the pathogen causing IE. We will also look at&#xD;
      perioperative complications, in particular, thromboembolic events and mortality at 30 and 90&#xD;
      days, and at 1 year.&#xD;
&#xD;
      These outcomes may help us optimise perioperative care for high-risk endocarditis patients,&#xD;
      and in particular those undergoing valve surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Any thromboembolic complications occuring between surgery and 1 year post operatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of perioperative coagulation abnormalities</measure>
    <time_frame>First 24 hours after surgery</time_frame>
    <description>How often perioperative coagulation abnormalities are seen from diagnosis to 24 hours post-surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in incidence of pathogens and the relation with disease severity</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>To evaluate the effect of different pathogens on the clinical status</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Endocarditis</condition>
  <condition>Coagulation Disorder</condition>
  <condition>Valve Disease, Heart</condition>
  <arm_group>
    <arm_group_label>Infective endocarditis, surgical arm</arm_group_label>
    <description>Patients with infective endocardits requiring valve surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infective endocarditis, conservative arm</arm_group_label>
    <description>Patients with infective endocardits, not requiring valve surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valve disease, heart, surgically repaired</arm_group_label>
    <description>Patients requiring valve surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None, observational</intervention_name>
    <description>Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery</description>
    <arm_group_label>Infective endocarditis, conservative arm</arm_group_label>
    <arm_group_label>Infective endocarditis, surgical arm</arm_group_label>
    <arm_group_label>Valve disease, heart, surgically repaired</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of two groups (a study group and a control group) of male&#xD;
        and female patients, 18 years and older. The study group consists of all patients with&#xD;
        infective endocarditis admitted to the Amsterdam UMC, in either location. Endocarditis&#xD;
        patients undergoing valve surgery will also be compared to patients undergoing similar&#xD;
        surgery for non-infectious reasons (control group).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years&#xD;
&#xD;
          -  Dutch or English speaking&#xD;
&#xD;
          -  All patients with infective endocarditis admitted to Amsterdam UMC in the study period&#xD;
&#xD;
          -  All patients with infective endocarditis scheduled for cardiac valve surgery compared&#xD;
             to a matched cohort of patients scheduled for similar surgery due to non-infectious&#xD;
             indication in Amsterdam UMC in the same period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of coagulation disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus W Hollmann, MD,PhD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam Academic Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer S Breel, MPA,MSc</last_name>
    <phone>+31610019257</phone>
    <email>j.s.breel@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henning Hermanns, MD,PhD</last_name>
    <phone>+31205669111</phone>
    <phone_ext>62533</phone_ext>
    <email>h.hermanns@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009 Mar 9;169(5):463-73. doi: 10.1001/archinternmed.2008.603.</citation>
    <PMID>19273776</PMID>
  </reference>
  <reference>
    <citation>Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, Hirsch GA, Mehta JL. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015 May 19;65(19):2070-6. doi: 10.1016/j.jacc.2015.03.518.</citation>
    <PMID>25975469</PMID>
  </reference>
  <reference>
    <citation>Cahill TJ, Prendergast BD. Infective endocarditis. Lancet. 2016 Feb 27;387(10021):882-93. doi: 10.1016/S0140-6736(15)00067-7. Epub 2015 Sep 1. Review.</citation>
    <PMID>26341945</PMID>
  </reference>
  <reference>
    <citation>Durante-Mangoni E, Molaro R, Iossa D. The role of hemostasis in infective endocarditis. Curr Infect Dis Rep. 2014 Nov;16(11):435. doi: 10.1007/s11908-014-0435-8.</citation>
    <PMID>25230604</PMID>
  </reference>
  <reference>
    <citation>Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? Circulation. 2010 Mar 9;121(9):1141-52. doi: 10.1161/CIRCULATIONAHA.108.773598. Review.</citation>
    <PMID>20212293</PMID>
  </reference>
  <reference>
    <citation>Buyukasýk NS, Ileri M, Alper A, Senen K, Atak R, Hisar I, Yetkin E, Turhan H, Demirkan D. Increased blood coagulation and platelet activation in patients with infective endocarditis and embolic events. Clin Cardiol. 2004 Mar;27(3):154-8.</citation>
    <PMID>15049384</PMID>
  </reference>
  <reference>
    <citation>Na S, Shim JK, Chun DH, Kim DH, Hong SW, Kwak YL. Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass. World J Surg. 2009 Sep;33(9):1862-7. doi: 10.1007/s00268-009-0107-2.</citation>
    <PMID>19597879</PMID>
  </reference>
  <reference>
    <citation>Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. J Thromb Thrombolysis. 2012 Jul;34(1):132-4. doi: 10.1007/s11239-012-0692-z.</citation>
    <PMID>22302637</PMID>
  </reference>
  <reference>
    <citation>Yu S, Khalpey ZI, Wong RK, Huynh T, Nielsen VG. Complete antithrombin replacement for anticoagulation for cardiopulmonary bypass to repair severe infective mitral valve endocarditis. Blood Coagul Fibrinolysis. 2018 Jan;29(1):123-125. doi: 10.1097/MBC.0000000000000668.</citation>
    <PMID>28957943</PMID>
  </reference>
  <reference>
    <citation>Ileri M, Alper A, Senen K, Durmaz T, Atak R, Hisar I, Yetkin E, Turhan H, Demirkan D. Effect of infective endocarditis on blood coagulation and platelet activation and comparison of patients with to those without embolic events. Am J Cardiol. 2003 Mar 15;91(6):689-92.</citation>
    <PMID>12633799</PMID>
  </reference>
  <reference>
    <citation>Salis S, Mazzanti VV, Merli G, Salvi L, Tedesco CC, Veglia F, Sisillo E. Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery. J Cardiothorac Vasc Anesth. 2008 Dec;22(6):814-22. doi: 10.1053/j.jvca.2008.08.004. Epub 2008 Oct 22.</citation>
    <PMID>18948034</PMID>
  </reference>
  <reference>
    <citation>Salsano A, Giacobbe DR, Sportelli E, Olivieri GM, Natali R, Prevosto M, Del Bono V, Viscoli C, Santini F. Aortic cross-clamp time and cardiopulmonary bypass time: prognostic implications in patients operated on for infective endocarditis. Interact Cardiovasc Thorac Surg. 2018 Sep 1;27(3):328-335. doi: 10.1093/icvts/ivy085.</citation>
    <PMID>29579243</PMID>
  </reference>
  <reference>
    <citation>Dahn H, Buth K, Legare JF, Mingo H, Kent B, Whynot S, Scheffler M. Endocarditis is not an Independent Predictor of Blood Transfusion in Aortic Valve Replacement Patients With Severe Aortic Regurgitation. J Cardiothorac Vasc Anesth. 2016 Jun;30(3):687-91. doi: 10.1053/j.jvca.2015.10.003. Epub 2015 Oct 9.</citation>
    <PMID>26750645</PMID>
  </reference>
  <reference>
    <citation>Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ, Choi YH, Wahlers T. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res. 2016 Jun 15;203(2):424-33. doi: 10.1016/j.jss.2016.03.008. Epub 2016 Mar 26.</citation>
    <PMID>27363652</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Jennifer Breel</investigator_full_name>
    <investigator_title>drs.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

